Consistent with this, ALDOB reintroduction in gastric cancer cells was shown to downregulate key glycolytic enzymes, leading to reduced lactate production and an overall decrease in cancer cell energy metabolism; consequently, these metabolic changes increased the cells' sensitivity to the chemotherapeutic agent Talazoparib 193. Here, ALDOB is linked to gastric cancer.